Clinically, we can’t generalize which one is more effective, Sindilizumab or K-drug, they are both immune drugs used for advanced cancer treatment, due to the different types of cancer diseases, or different sensitivity to immune drugs and other reasons, resulting in differences in the final therapeutic effect of patients. Sindilizumab is a kind of domestic intravenous immune drug, and its indications include classic Hodgkin’s lymphoma, advanced hepatocellular liver cancer, advanced non-small cell lung cancer and so on. K drug generally refers to pembrolizumab, which is an imported intravenous immune drug, and its indications include advanced non-small cell lung cancer, advanced melanoma, advanced esophageal cancer, squamous cell carcinoma of the head and neck, and advanced colorectal cancer. There are no clinical studies comparing the effects of these two immune drugs, so it is not clear which one is more effective.